ClinicalTrials.gg
Active, not recruitingNCT04947319Updated Mar 30, 2026

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

A Phase 2 interventional study of Tirabrutinib and Tirabrutinib in Refractory Primary Central Nervous System Lymphoma and Primary CNS Lymphoma, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 39 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
119
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)

02

Conditions studied

  • Refractory Primary Central Nervous System Lymphoma
  • Primary CNS Lymphoma

Keywords

  • Bruton's Tyrosine Kinase Inhibitor, BTKi, tirabrutinib, ONO-4059, PROSPECT
03

In context

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Part A)

  1. Written by the patient prior to screening
  2. Patients aged ≥ 18 years on the day of consenting to the study
  3. Pathologic diagnosis of PCNSL
  4. Relapse or PCNSL with at least one prior high dose methotrexate (HD-MTX) based therapy for PCNSL
  5. Measurable brain lesion with a minimum diameter > 1.0 cm in gadolinium enhanced magnetic resonance imaging (MRI) performed within 14 days before starting tirabrutinib treatment
  6. performance score (ECOG PS) of 0, 1 or 2
  7. of at least 3 months
  8. Adequate bone marrow, renal, and hepatic function

Inclusion Criteria (Part B)

  1. Written informed consent by the patient prior to screening
  2. Patients aged ≥ 18 years on the day of consenting to the study
  3. Pathologic diagnosis of PCNSL within the past 3 months
  4. No prior anti-tumor treatments for PCNSL
  5. Patients who, in the opinion of the Investigator, are suitable to receive treatment with a high dose methotrexate containing regimen
  6. Measurable brain lesion with a minimum diameter > 1.0 cm in gadolinium enhanced MRI performed within 14 days before starting study treatment
  7. ECOG PS of 0, 1 or 2
  8. Life expectancy of at least 6 months
  9. Adequate bone marrow, renal, and hepatic function

Exclusion Criteria (Part A)

  1. Intraocular PCNSL with no brain lesion
  2. Patient who is intolerant of contrast enhanced MRI due to allergic reactions to contrast agents
  3. Patient with non-B cell PCNSL
  4. Patient with systemic presence of lymphoma
  5. Prior chemotherapy within 21 days, nitrosourea within 42 days, an antibody drug with anticancer activity (e.g., rituximab) within 28 days, prior radiotherapy within 14 days, prior major invasive surgery within 28 days, or stem cell transplant within 6 months before starting tirabrutinib treatment
  6. Prior BTK inhibitor treatment
  7. Prior drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment
  8. Concomitant systemic on an ongoing basis within 14 days before starting tirabrutinib treatment, with the exception of the following:

    • Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL
    • Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for patients with lesions of the brain or spinal cord or both
  9. Patient who has received a inducer or P-gp inducer within 14 days before starting tirabrutinib treatment
  10. Concomitant warfarin, any other warfarin derivative anticoagulant, vitamin K antagonists, novel oral anticoagulants, or antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment
  11. Active , other than PCNSL requiring systemic therapy
  12. Poorly controlled comorbidity, severe heart, severe lung disease, liver diseases that could affect protocol compliance or safety or efficacy assessments
  13. Patient with bleeding diathesis
  14. Patients with a history of moderate or severe hepatic impairment
  15. > 480 milliseconds or requirement for ongoing treatment with concomitant medications that prolong the QT interval
  16. Active infection, including a , cytomegalovirus infection or SARS-CoV-2, or has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic
  17. Prior history of or anaphylaxis to tirabrutinib
  18. Prior history of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis
  19. Medical history of organ allografts
  20. Tests positive for HIV-1 antibody and HIV-2 antibody, human T-lymphotropic virus 1 antibody, (HB) antigen, or virus (HCV) antibody. Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen.
  21. Patient is unable to swallow tablets; has malabsorption, malabsorption syndrome, or a comorbidity that affects gastric function; has undergone complete resection of the stomach or small intestine; has ulcerative colitis or symptomatic inflammatory bowel disease; or has partial or complete intestinal obstruction.
  22. Women who are pregnant or lactating
  23. Patient is found incapable of giving consent due to dementia or another such condition
  24. Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.

Exclusion Criteria (Part B)

  1. Intraocular PCNSL with no brain lesion
  2. Patients for whom the selected backbone regimen medications (i.e, methotrexate/temozolomide/rituximab for MTR and rituximab/methotrexate/procarbazine/vincristine for R-MPV) are
  3. Patients with a history of intolerable toxicity, hypersensitivity, anaphylaxis to the selected backbone regimen medications
  4. Patient who is intolerant of contrast enhanced MRI due to allergic reactions to contrast agents
  5. Patient with non-B cell PCNSL
  6. Patient with systemic presence of lymphoma
  7. Prior chemotherapy within 21 days, nitrosourea within 42 days, an antibody drug with anticancer activity (e.g., rituximab) within 28 days, prior radiotherapy within 14 days, prior major invasive surgery within 28 days, or allogeneic stem cell transplant within 6 months before starting tirabrutinib treatment
  8. Prior BTK inhibitor treatment
  9. Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment
  10. Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment, with the exception of the following:

    • Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL
    • Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for patients with lesions of the brain or spinal cord or both
  11. Patient who has received a CYP3A4 inducer or P-gp inducer within 14 days before starting tirabrutinib treatment
  12. Concomitant warfarin, any other warfarin derivative anticoagulant, vitamin K antagonists, novel oral anticoagulants, or antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment
  13. Active malignancy, other than PCNSL requiring systemic therapy
  14. Poorly controlled comorbidity, severe heart, severe lung disease, clinically significant liver diseases that could affect protocol compliance or safety or efficacy assessments
  15. Patient with bleeding diathesis
  16. Patients with a history of moderate or severe hepatic impairment
  17. QTcF > 480 milliseconds or requirement for ongoing treatment with concomitant medications that prolong the QT interval
  18. Active infection, including a HIV, cytomegalovirus infection or SARS-CoV-2, or has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic
  19. Prior history of hypersensitivity or anaphylaxis to tirabrutinib
  20. Prior history of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis
  21. Medical history of organ allografts
  22. Tests positive for HIV-1 antibody and HIV-2 antibody, human T-lymphotropic virus 1 antibody, HBs antigen, or HCV antibody. Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen.
  23. Patient is unable to swallow tablets; has malabsorption, malabsorption syndrome, or a comorbidity that affects gastric function; has undergone complete resection of the stomach or small intestine; has ulcerative colitis or symptomatic inflammatory bowel disease; or has partial or complete intestinal obstruction.
  24. Women who are pregnant or lactating
  25. Patient is found incapable of giving consent due to dementia or another such condition
  26. Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A)

    Patients with relapsed or refractory PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib monotherapy.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib + MTR in patients with newly diagnosed, treatment naïve PCNSL (Part B, Arm 1)

    Patients with newly diagnosed treatment naïve PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib + methotrexate/temozolomide/rituximab (MTR)

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib + R-MPV in patients with newly diagnosed, treatment naïve PCNSL (Part B, Arm 2)

    Patients with newly diagnosed treatment naïve PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib + rituximab/methotrexate/procarbazine/vincristine (R-MPV)

    Drug: Tirabrutinib

Interventions

  • Part A: Tirabrutinib 480 mg, taken orally, once a day on an empty stomach. Tirabrutinib treatment may be continued until disease progression or clinically unacceptable toxicity is observed.

    Also known as: ONO-4059

  • Part B, Arm 1 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an MTR induction regimen. Tirabrutinib with MTR treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed. For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment.

    Also known as: ONO-4059

  • Part B, Arm 2 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an R-MPV induction regimen. Tirabrutinib with R-MPV treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed. For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment.

    Also known as: ONO-4059

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR) (Part A)

    Overall response rate is defined as the proportion of patients with a best overall response of Complete response (CR), Complete response - unconfirmed (CRu), or (=partial response (PR) as determined by an independent review committee according to the International PCNSL Collaborative Group (IPCG) criteria.

    Time frame: 1 year

  2. Tirabrutinib dose estimate (Part B)

    Estimate of tirabrutinib dose in combination with each backbone induction regimen (MTR and R-MPV) based upon treatment related AEs, SAEs, and toxicities observed during the initial cycle of induction therapy in the dose-ranging phase

    Time frame: 1 month

  3. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) during induction (Part B)

    Adverse events at each visit with the NCI CTCAE v5.0 used as a guide for the grading of severity.

    Time frame: 4 months

  4. Complete response rate (CRR) (Part B)

    Complete response rate is defined as the proportion of patients with a best overall response of CR or CRu as determined by an independent review committee according to the IPCG criteria.

    Time frame: 4 months

Secondary outcomes

  1. Duration of response (DOR) (Part A and B)

    Duration of response is defined as the time between the date of first response (CR, CRu, or PR) and the date of the first PD according to the IPCG criteria, or date of death due to any cause, whichever occurs first.

    Time frame: 2 years

  2. Time to response (TTR) (Part A and B)

    Time to response is defined as the time between the date of first administration of tirabrutinib and the date of first response (CR, CRu, or PR) as determined by IRC according to the IPCG criteria.

    Time frame: 1 year

  3. Best overall response (BOR) (Part A and B)

    Best overall response based on independent review committee (IRC) response determination is defined as the best response and is derived programmatically based upon the visit responses determined by IRC from the date of administration of tirabrutinib to the date of PD as determined by IRC or the date of initiation of subsequent anticancer therapy for PCNSL, whichever occurs first.

    Time frame: 1 year

  4. Change in corticosteroid dose (Part A)

    Descriptive statistics will be calculated for the actual corticosteroid dose and the change from baseline at each assessment point.

    Time frame: 2 years

  5. Incidence and severity of AEs and SAEs (Part A and B)

    Adverse events at each visit with the NCI CTCAE v5.0 used as a guide for the grading of severity.

    Time frame: 2 years

  6. Laboratory abnormality profile of tirabrutinib as measured by incidence and severity of clinical laboratory abnormalities (Part A and B)

    Results of laboratory tests

    Time frame: 2 years

  7. ECG parameters by 12 lead ECG (Part A and B)

    Heart rate, RR and QT intervals, QTc (QTcF, QTcB), PR interval, and QRS width.

    Time frame: 2 years

  8. PK parameters (Cmax) of tirabrutinib in the plasma (Part A and B)

    Time frame: 29 days

  9. PK parameters (Tmax) of tirabrutinib in the plasma (Part A and B)

    Time frame: 29 days

  10. PK parameters (AUC) of tirabrutinib in the plasma (Part A and B)

    Time frame: 29 days

07

Study locations

39 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jan 2026, 48 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2021
First posted
Jul 1, 2021
StartActual
Dec 29, 2021
Primary completionActual
Jan 27, 2026
CompletionEst.
Mar 31, 2027
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04947319
Responsible party
Sponsor
First posted
Jul 1, 2021
Start date
Dec 29, 2021
Primary completion
Jan 27, 2026
Completion
Mar 31, 2027 (estimated)
Last update
Mar 30, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirabrutinib

Start the discussion